Abstract
Combined immunotherapy using checkpoint blockade (anti-CTLA4 and anti-PD-1) and the DPP4 inhibitor sitagliptin reveals the existence of a T cell– and eosinophil-targeted immunotherapy approach for solid tumors.
Original language | English |
---|---|
Pages (from-to) | 250-252 |
Number of pages | 3 |
Journal | Nature Immunology |
Volume | 20 |
Issue number | 3 |
DOIs |
|
State | Published - 1 Mar 2019 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology